Form 8-K VERTEX PHARMACEUTICALS For: Jan 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vertex (VRTX) PT Raised to $285 at SunTrust
January 31, 2020 6:40 AM ESTSunTrust analyst Robyn Karnauskas raised the price target on Vertex (NASDAQ: VRTX) to $285.00 (from $235.00) while maintaining a Buy rating following results.
The analyst commented, "Recent approval of VRTX's drug TRIKAFTA and strong early launch metrics de-risk CF revenues for VRTX, in our... More
